Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Uniphar PLC ( (GB:UPR) ) just unveiled an update.
Uniphar reported an estimated 21% growth in adjusted earnings per share for 2025, ahead of expectations, driven by approximately 9% organic gross profit growth, lower finance costs and the accretive impact of a €35m share buy-back programme. The group ended the year with a stronger-than-expected balance sheet, posting Net Bank Debt to EBITDA of 1.5x due to favourable working capital movements, and signalled confidence in continued organic growth in 2026, targeting double‑digit organic gross profit growth in Pharma, high single digits in Medtech and low single digits in Supply Chain & Retail, underpinned by an active but disciplined M&A strategy and a stated ambition to reach €200m in EBITDA by 2028.
More about Uniphar PLC
Uniphar plc is an international diversified healthcare services group operating across pharma, medtech, and supply chain & retail. The company focuses on providing commercial and clinical services to pharmaceutical and medical technology manufacturers, as well as wholesale and retail distribution of healthcare products, with operations that span multiple markets from its bases in Dublin and London.
For an in-depth examination of UPR stock, go to TipRanks’ Overview page.